Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McMaster University
$105,000.00
Potentiating Gram-Positive Antibiotics in Gram-Negative Bacteria
FY 2017-18
Summary
The World Health Organization has revealed a list of 12 groups of bacteria that pose the highest risk to human health for which new treatments are needed. A vast majority of the bacteria on this list are classified as Gram-negative, a type of bacteria that possess an outer membrane structure. This outer membrane protects the bacterial cell from chemicals in the environment, including antibiotics. Many of the antibiotics in clinical use are not effective against Gram-negative bacteria, as they cannot penetrate the outer membrane barrier. Altering outer membrane integrity is important for allowing these antibiotics to enter impermeable Gram-negative cells and treat these bacterial infections. Our research group has previously uncovered 41 genes involved in resistance to vancomycin, an antibiotic that cannot penetrate the outer membrane of Gram-negative bacterium Escherichia coli (E. coli). We are undertaking a large-scale study to examine which genes, when deleted in combination with those 41 genes, will allow entry of the impermeable antibiotics vancomycin and rifampicin through the outer membrane to kill E. coli cells. Upon discovering which pairs of gene deletions compromise outer membrane integrity, we will screen 1,600 Food and Drug Administration (FDA) approved drugs to find molecules that target those gene pairs. Our goal is to find a combination of molecules that enable antibiotic penetration through the Gram-negative outer membrane. This would open up new treatment avenues through combination therapy for these hard-to-treat, intrinsically resistant infections.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
383348
Name
Klobucar Kristina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
Potentiating Gram-Positive Antibiotics in Gram-Negative Bacteria
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Antibiotic Resistance; Bacterial Conjugation; Genetic Interaction Network; Gram-Negative Bacteria; High-Throughput Screening; Molecular Cloning; Outer Membrane; Pcr; Synthetic Genetic Arrays; Synthetic Lethality
Abstract
The World Health Organization has revealed a list of 12 groups of bacteria that pose the highest risk to human health for which new treatments are needed. A vast majority of the bacteria on this list are classified as Gram-negative, a type of bacteria that possess an outer membrane structure. This outer membrane protects the bacterial cell from chemicals in the environment, including antibiotics. Many of the antibiotics in clinical use are not effective against Gram-negative bacteria, as they cannot penetrate the outer membrane barrier. Altering outer membrane integrity is important for allowing these antibiotics to enter impermeable Gram-negative cells and treat these bacterial infections. Our research group has previously uncovered 41 genes involved in resistance to vancomycin, an antibiotic that cannot penetrate the outer membrane of Gram-negative bacterium Escherichia coli (E. coli). We are undertaking a large-scale study to examine which genes, when deleted in combination with those 41 genes, will allow entry of the impermeable antibiotics vancomycin and rifampicin through the outer membrane to kill E. coli cells. Upon discovering which pairs of gene deletions compromise outer membrane integrity, we will screen 1,600 Food and Drug Administration (FDA) approved drugs to find molecules that target those gene pairs. Our goal is to find a combination of molecules that enable antibiotic penetration through the Gram-negative outer membrane. This would open up new treatment avenues through combination therapy for these hard-to-treat, intrinsically resistant infections.
Competitiondate
201710
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Klobucar, Kristina
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~